Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

Descriptions

NHS England has taken the decision to abandon this competitive provider selection process (effective from 30th June 2025) for lifileucel, a cellular therapy for previously treated unresectable or metastatic melanoma (NICE ID 3863). NHS England remains committed to commissioning this service, as this tumour infiltrating lymphocyte cell therapy progresses through the NICE TA process, in line with the relevant procurement regulations and intends to progress this at the earliest suitable opportunity. Any future opportunities will be advertised in line with these the relevant procurement regulations, for example via the Find a Tender Service, and we will also notify all providers registered against the current process.This is a Provider Selection Regime (PSR) notice that this provider selection process has been abandoned and a contract has not been awarded. This process has been abandoned under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.

VII.1.2) Text to be corrected in the original notice
Section number
II.1.4.1

Instead of
Text
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Read
Text
NHS England has taken the decision to abandon this competitive provider selection process (effective from 30th June 2025) for lifileucel, a cellular therapy for previously treated unresectable or metastatic melanoma (NICE ID 3863). NHS England remains committed to commissioning this service, as this tumour infiltrating lymphocyte cell therapy progresses through the NICE TA process, in line with the relevant procurement regulations and intends to progress this at the earliest suitable opportunity. Any future opportunities will be advertised in line with these the relevant procurement regulations, for example via the Find a Tender Service, and we will also notify all providers registered against the current process.This is a Provider Selection Regime (PSR) notice that this provider selection process has been abandoned and a contract has not been awarded. This process has been abandoned under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.